“This donation is a small way to express my admiration for Opportunity Project’s work and its impact on so many lives,” said Dr. Saadi. “As a fellow New Jersey organization, we share a deep commitment ...

WARREN, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced that its Founder and CEO, Dr. Ryan Saadi, has donated 10,000 of his ...

The Company remains on track to initiate the HCW9302 clinical trial in the third quarter of 2025. This trial is a first-in-human Phase 1 dose escalation clinical trial to evaluate one of its lead drug ...

To help close this prevention gap in Florida, a new health platform, WePrevent.org, launched today with a mission to shift ...

First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE ...

Photo: Founder and Chief Dentist Dr. Mehmet İşlek of Attelia Dental Clinic receiving the Quality Choice Prize 2025 award.

Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.

WOODCLIFF LAKE, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its 2025 Annual Meeting of Stockholders (the “2025 ...

Mont-Saint-Guibert, Belgique – 18 août 2025, 22h10 CET / 16h10 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale développant des ...

DALLAS, Aug. 18, 2025 (GLOBE NEWSWIRE) -- BioNTX is pleased to announce the finalists for the Annual Southwest Tech Transfer Showcase, set for Wednesday, September 17th, at the 2025 iC³® Life Science ...

WESTBROOK, Maine, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a leading consumer health and wellness company, today announced a major retail ...

Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ...